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Abstract
Background: Depletion of replication factors often causes cell death in cancer cells. Depletion of Cdc7, a kinase essential for
initiation of DNA replication, induces cancer cell death regardless of its p53 status, but the precise pathways of cell death
induction have not been characterized.
Methodology/Principal Findings: We have used the recently-developed cell cycle indicator, Fucci, to precisely characterize
the cell death process induced by Cdc7 depletion. We have also generated and utilized similar fluorescent cell cycle
indicators using fusion with other cell cycle regulators to analyze modes of cell death in live cells in both p53-positive and -
negative backgrounds. We show that distinct cell-cycle responses are induced in p53-positive and -negative cells by Cdc7
depletion. p53-negative cells predominantly arrest temporally in G2-phase, accumulating CyclinB1 and other mitotic
regulators. Prolonged arrest at G2-phase and abrupt entry into aberrant M-phase in the presence of accumulated CyclinB1
are followed by cell death at the post-mitotic state. Abrogation of cytoplasmic CyclinB1 accumulation partially decreases
cell death. The ATR-MK2 pathway is responsible for sequestration of CyclinB1 with 14-3-3s protein. In contrast, p53-positive
cancer cells do not accumulate CyclinB1, but appear to die mostly through entry into aberrant S-phase after Cdc7 depletion.
The combination of Cdc7 inhibition with known anti-cancer agents significantly stimulates cell death effects in cancer cells
in a genotype-dependent manner, providing a strategic basis for future combination therapies.
Conclusions: Our results show that the use of Fucci, and similar fluorescent cell cycle indicators, offers a convenient assay
system with which to identify cell cycle events associated with cancer cell death. They also indicate genotype-specific cell
death modes induced by deficient initiation of DNA replication in cancer cells and its potential exploitation for development
of efficient cancer therapies.
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Introduction
Cdc7 is a conserved serine-threonine kinase which plays a
critical role in the firing of replication origins [1–3]. A key
substrate is MCM, a component of the prereplicative complex
(pre-RC), and phosphorylation of the MCM2, 4 and 6 subunits of
the MCM complex by Cdc7 triggers the association of Cdc45 with
pre-RC, a crucial step for generation of an active replication fork
[4–6]. Cdc7 forms a complex with Dbf4, an activation subunit, to
generate an active kinase complex [2]. In humans, two activation
subunits, ASK and Drf1/ASKL1, are known to exist [2,7–9].
Knockout of Cdc7 in mice causes early embryonic lethality.
Inactivation of Cdc7 genes in mouse ES cells is also lethal [10];
cells cease DNA synthesis, accumulate DNA damages, and
eventually undergo cell death in a p53-dependent manner.
Knockdown experiments in mammalian cells indicate that ASK
is essential while Drf1/ASKL1 may be dispensable for viability
[9,11]. Indeed, inactivation of the ASK genes in mouse ES cells
also leads to lethality [12]. These results indicate that Cdc7-ASK is
essential for proliferation of mammalian cells. On the other hand,
Drf1/ASKL1 may play a predominant role as an activator of
Cdc7 in the early development of amphibians [13,14]. An
ortholog of Drf1/ASKL1 has not been identified in mice.
On a cellular level, knockdown of Cdc7 was shown to cause cell
death in cancer cells, but not in normal cells, in which p53-
dependent pathways arrest the cell cycle presumably in G1 phase
[15,16]. It was also reported that Cdc7 knockdown induced p38-
dependent cell death in HeLa cells [17]. However, Cdc7 depletion
causes cell death also in p53-positive cells, suggesting that p53
alone cannot prevent cell death induced by Cdc7 depletion in
cancer cells. At present, the precise mechanisms of p53-indepen-
dent cell death in Cdc7-depleted cancer cells are not known. In
this study, we analyzed the effect of Cdc7 depletion in cancer cells
by using the recently developed cell cycle indicator Fucci [18] as
well as similar fluorescent cell cycle indicators. Our results point to
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depleted cancer cells.
Results
Depletion of Cdc7 kinase in human cancer cells causes
cell death
Depletion of Cdc7 in HeLa, U2OS or other cancer cells with
siRNA resulted in inhibition of DNA synthesis, accumulation of
chromosome damages [represented by c-H2AX foci) and eventual
loss of viability viability [15,19,20]. Cell death was induced in both
p53-positive or p53-negative cancer cells, consistent with previous
reports [15,19]. FACS analyses of DNA content indicated that
Cdc7 depletion leads initially to decreased G1 population,
followed by increase of sub-G1 population, indicative of cell death
(Fig. S1A and Fig. S2B).
In order to investigate the mode of cell death induced by Cdc7
depletion, we used HeLa cells expressing the cell cycle indicator,
Fucci (Fluorescent ubiquitin-based cell cycle indicator; [18]),
which permits visualization of the cell cycle state (red for G1
and green for S/G2/M). HeLa-Fucci was transfected with Cdc7
siRNA and the cells were monitored to determine the cell cycle
stage at which they undergo cell death. Cell death occurs at both
post-mitotic G1 and during S/G2/M phase in HeLa-Fucci
(Fig. 1A and C, movies S1 and S2). We also generated
U2OS-Fucci and examined the cell death mode in U2OS after
Cdc7 depletion. In U2OS, more than 70% of the cells died during
S/G2/M phase (green; Fig. 1B and C). In contrast, Cdc7
depletion did not induce cell death in NHDF (normal human
dermal fibroblast) cells and led mostly to G1 arrest as described
previously (Fig. S1 and data not shown; [15]).
Cytoplasmic accumulation of CyclinB1 protein in Cdc7-
depleted HeLa cells
The FACS analysis of Cdc7-depleted HeLa cells did not show
accumulation of G2/M population (Fig. S1A and Fig. S2B).
However, Western analyses of various proteins after Cdc7
depletion in HeLa cells indicated that levels of CyclinB1, AuroraA
and Plk1 proteins increased (Fig. 1D, E and F). The levels of
both Cdc25C, Cdc25CS216 (Fig. 1E) and the tyrosine 15
phosphorylation of Cdc2 also increased (Fig. 1F), suggesting that
G2/M checkpoint may be induced in Cdc7-depleted HeLa cells.
Although the level of CyclinB1 protein increased, the CyclinB1-
dependent Cdc2 kinase activity was almost the same as that of the
control (Fig. 1F). This may be due to the association with 14-3-3
proteins, which may inhibit the kinase activity (see below), as well
as to the checkpoint-induced inhibitory tyrosine 15 phosphoryla-
tion. On the other hand, in p53-positive U2OS, depletion of Cdc7
did not cause CyclinB1 accumulation, and did not affect
CyclinB1-dependent Cdc2 kinase activity or tyrosine 15 phos-
phorylation of Cdc2 (Fig. 1F).
The staining and observation of M phase chromosomes
indicated an increase of aberrantly condensed chromosomes in
Cdc7 siRNA-treated cells (Fig. 1G). About 50% of the mitotic
cells exhibited the aberrantly condensed chromosomes in Cdc7-
depleted HeLa cells. Also, metaphase to telophase cell populations
decreased in Cdc7 siRNA-treated HeLa cells (Fig. 1H). These
results indicate that a large population of cells arrest or slow down
at G2 after depletion of Cdc7 kinase in HeLa cells with aberrantly
condensed chromosomes, and a portion of the cells die during G2/
M phase, possibly by metaphase. However, precise timing of cell
death during M phase has not been determined. In U2OS, there is
no significant difference for M phase chromosomes between Cdc7-
depleted and control cells. However, the numbers of apoptotic
nuclei increased after depletion of Cdc7 in U2OS (Fig. 1I). Thus,
these results also show that the timing of cell death induced by
Cdc7 depletion may differ in HeLa and U2OS cells.
We then analyzed the cellular localization of CyclinB1 protein
by immunostaining. We noted the increase of CyclinB1-positive
cells in Cdc7 siRNA-treated cells, as expected from an increase of
the overall CyclinB1 protein level. We also noted that a substantial
population of Cdc7-depleted HeLa cells contain CyclinB1 protein
in cytoplasm (Fig. 2A and B). To confirm this result, we
examined the effect of Cdc7 depletion using HeLa cells stably
expressing mKO2-fused CyclinB1 protein. In this cell line, the red
fluorescent signals first appeared in cytoplasm at about 10–14 hrs
after cell division. The signals were detectable for about 5–6 hrs.
Since the synchronization experiments suggest that G2/M phases
in HeLa cells last for about 3–5 hrs, CyclinB1 is likely to be
expressed from late S phase through metaphase. These signals
translocate into nuclei and disappear after metaphase (Fig. 2C,
upper panel; movie S3), consistent with the expected behavior
of the endogenous CyclinB1 protein, as shown previously [21–23].
When cells were treated with Cdc7 siRNA, the population of the
cells with strong cytoplasmic red signals increased, and these
signals stayed in the cytoplasm for a longer period (Fig. 2C,
lower panel and movie S4). The time required for transloca-
tion of the red signals into nuclei after its appearance in the
cytoplasm was a few hrs in the control cells, whereas it increased in
Cdc7-depleted cells (Fig. 2C and D, movies S3 and S4). This
was also observed with different Cdc7 siRNAs (Fig. S2 and data
not shown). These results are consistent with the idea that
CyclinB1 accumulates in the cytoplasm in HeLa cells treated with
Cdc7 siRNA. We also generated HeLa cells expressing mKO2-
AuroraA. Expression and activity of AuroraA, one of the mitotic
kinases, is known to peak at the G2/M phase [24]. Consistently,
the AuroraA signals appeared at G2 phase, and disappeared at the
end of M phase in control cells, while the duration of the AuroraA
signals became much longer after Cdc7 depletion (Fig. S3,
movies S5 and S6). This effect was again seen with other Cdc7
siRNAs (Fig. S3C and data not shown). These results indicate
that Cdc7 depletion causes the G2 cell cycle delay in HeLa cells
concomitant with increased CyclinB1 and AuroraA protein levels.
Many Cdc7-depleted cells with high cytoplasmic CyclinB1
abruptly enter mitosis after lengthy G2 arrest, and very often
undergo apparent cell death in the following hours. This is similar
to the mitotic catastrophe reported previously [25], but the cells
are restrained from proceeding into M phase by inhibition of
nuclear translocation of CyclinB1, not at the stage of spindle
checkpoint, as reported previously in a different system [26].
Indeed, abrogation of the spindle checkpoint by siRNA targeted to
Mad2 did not affect the CyclinB1 retention in cytoplasm that
occurs in response to Cdc7 depletion in HeLa cells (data not
shown).
14-3-3s sequesters CyclinB1 in the cytoplasm after Cdc7
depletion
The next question is how CyclinB1 accumulates in the
cytoplasm. 14-3-3s is conserved, well-characterized factors,
known to bind to various cell cycle regulators and retain them
in cytoplasm in some circumstances [25]. Each of the seven 14-3-3
isoforms was expressed, and its interaction with Cdc2-CyclinB1
was examined. 14-3-3s was among the strongest binders (data not
shown). We examined whether the accumulated CyclinB1 is
bound to 14-3-3s in Cdc7-depleted HeLa cells and found that
CyclinB1-bound 14-3-3s significantly increased in Cdc7-depleted
cells (Fig. 3A, lane 2). Also, immunoprecipitation of transiently
expressed 14-3-3s after Cdc7 depletion showed that CyclinB1 and
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Figure 1. Cdc7 depletion in cancer cells induces cell death: effect on Cdc2-CyclinB1 and mitosis. (A and B) HeLa (A) or U2OS (B) cells
expressing Fucci were treated with control or Cdc7-D siRNA, and time lapse image was recorded with Olympus LCV100 (movies S1 and S2). Images
taken from the time lapse data at the times indicated are presented. The uppermost panels (control siRNA) indicate cells undergoing normal cell
division. Numbers in each panel show time (hrs) after siRNA transfection. Lower two panels (a and b) show Cdc7 siRNA treated cells. Some cells died
in red color (G1 phase, a), and other cells died in green (S/G2/M phase, b). Lengths of cell cycle stages are indicated in the panels (G1, arrowed broken
lines; S/G2/M, arrowed solid lines). Bar, 20 mm. (C) Dead cells in Cdc7 siRNA-treated HeLa-Fucci (left, 324 cells) or U2OS-Fucci (right, 180 cells) were
counted from the time lapse data to determine the fractions of the dead cells in red and in green. Cell death occurs at both G1 and S/G2/M phases in
Cdc7 siRNA treated cancer cells. (D, E and F) HeLa cells were transfected with control or Cdc7-D siRNA and were harvested at 48 hrs (D) or at the
times indicated (E and F). The whole cell extracts (D) or CSK-soluble extracts (E) were analyzed by western blotting using the antibodies indicated.
(F) Cdc2-CyclinB1 kinase activity was measured using the CSK-soluble extracts. The immunoprecipitates (IP) used for the assays and the input extracts
were analyzed by western blotting. The extent of Cdc7 depletion was similar between HeLa and U2OS. Cdc7 was not detectable by western after
siRNA treatment in both cells. (G) HeLa cells were treated with control or Cdc7-D siRNA for indicated times, collected, washed with PBS, swollen in
75 mM KCl for 20 min at 37uC, and fixed with glacial acetic acid/methanol (1:3) solution three times. Fixed chromosomes were dropped on a slide
Cancer Cell Death Induced by Replication Defect
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detect the association of 14-3-3s and Cdc25C, as previously
described [25,27]. These results suggest that 14-3-3s sequesters
the Cdc2-CyclinB1 complex in the cytoplasm after Cdc7 depletion
in HeLa cells.
Reduction of cytoplasmic accumulation of CyclinB1
partially reduces cell death
Since cells accumulating CyclinB1 in the cytoplasm are prone to
cell death, we examined if reduction of cytoplasmic CyclinB1
antagonizes the cell death effect of Cdc7 depletion. Co-depletion
of both Cdc7 and 14-3-3s in HeLa cells reduced the CyclinB1,
AuroraA, Plk1 and Cdc25C protein levels (Fig. 3C). The time
glass, air dried and stained with 5% Giemsa’s solution in 1/15 M PBS. Spread chromosomes were observed under All-in-One microscopy (Keyence).
The mitotic cells with aberrantly condensed chromosomes were counted and the fractions are presented. The insets show representative images of
aberrantly condensed chromosomes observed in a Cdc7 siRNA treated HeLa cell (left) and properly condensed chromosomes observed in a control
cell (right). Bar, 50 mm. (H) HeLa cells were treated with control or Cdc7-D siRNA for 48 hrs, washed with PBS, fixed with 4% paraformaldehyde for
10 min at room temperature and then stained with Hoechst 33342. Cells were examined under confocal microscopy LSM510 (1427 cells [Cdc7] and
1023 cells [control]), and the cells in M phase stages were scored. The fractions of cells in each mitotic stage are presented. (I) Spread and fixed
chromosomes prepared in U2OS as described above were observed by FSX100 Olympus microscopy. No significant difference was observed in
mitotic cells after Cdc7 depletion. However, the numbers of apoptotic cells increased in Cdc7-depleted U2OS cells. Bar, 32 mm. In C, G and H, ‘‘n’’
represents the numbers of independent experiments conducted.
doi:10.1371/journal.pone.0036372.g001
           
Figure 2. Cdc7 depletion in HeLa cells leads to accumulation of cytoplasmic CyclinB1. (A) HeLa cells were cultured on cover glasses,
transfected with control or Cdc7-D siRNA for 48 hrs, fixed with 4% paraformaldehyde and stained by anti-CyclinB1 antibody followed by FITC-
conjugated anti-mouse IgG and Hoechst33342. Left, Cdc7 siRNA; right, control siRNA. Green, CyclinB1; blue, DNA. Photos were taken by FSX100
Olympus microscopy. Bar, 16 mm. (B) More than 3,000 cells were examined and cells with nuclear CyclinB1 signals were scored and the fractions are
presented. ‘‘n’’ represents the numbers of independent experiments conducted. (C) HeLa cells expressing mKO2-CyclinB1 were treated with Cdc7-D
siRNA or control siRNA. Time lapse images were recorded by Olympus LCV100 (movies S3 and S4). Images taken from the time lapse data at the
times indicated are presented. Upper, control siRNA; lower, Cdc7 siRNA. Red signals show mKO2-CyclinB1. The control siRNA-treated cells indicate
those undergoing periodic cytoplasmic appearance, nuclear transfer, and degradation (upper panel), whereas the Cdc7 siRNA-treated cells show
persistent strong cytoplamic signals for a long period (lower panel). Numbers in each panel show time (hrs) after siRNA treatment. Bar: 20 mm. (D) The
time (hr) between the first appearance of cytosolic mKO2-CyclinB1 signal and its translocation into the nucleus was measured in the time lapse
images of control or Cdc7-D siRNA treated HeLa cells. The P-value of the two-tailed unpaired t-test was calculated by Prism software.
doi:10.1371/journal.pone.0036372.g002
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sub-G1 cell population decreased (Fig. 3D and E). These findings
suggested that the absence of 14-3-3s facilitates the G2-M
transition and progression into the next cell cycle stage, partially
rescuing the cells from cell death.
We next expressed mKO2-NLS-CyclinB1, which constitutively
localizes in nuclei in HeLa cells at late S through metaphase. In
these cells, the time required for transition from late S to G2/M
was shortened compared to mKO2-CyclinB1 expressing cells and
cell death was partially circumvented at 48 hrs after Cdc7
depletion (Fig. 4A and B). This is consistent with a previous
report that ectopic expression of NLS-CyclinB1 in HeLa cells
reduced the G2-delay occurring in response to X-ray irradiation
[28]. However, cells expressing mKO2-NLS-CyclinB1 still under-
went apoptosis at later time points after Cdc7 depletion. This may
be expected since expression of nuclear CyclinB1 is known to
induce apoptosis in cancer cells [29]. Co-depletion of CyclinB1
reduced G2-elongation and partially rescued the cell death
induced by Cdc7 depletion (Fig. 4C, D). These results support
the notion that cytoplasmic accumulation of CyclinB1 and its
abrupt translocation into nuclei are at least partially responsible
for the observed cell death in HeLa cells induced by Cdc7
depletion and that the cell death can be at least partially prevented
by facilitating mitosis.
G2 elongation is caused by depletion of Cdc7 in p53-
negative cells through MK2 activation
It was previously reported that the p38-MK2 pathway is
activated in HeLa cells by depletion of Cdc7 [17]. Therefore, we
examined whether this pathway is involved in cytoplasmic
accumulation of CyclinB1 in Cdc7-depleted HeLa cells. First,
Figure 3. 14-3-3s sequesters CyclinB1 in the cytoplasm in Cdc7-depleted HeLa cells. (A) HeLa cells were treated with control or Cdc7-D
siRNA for 24 hrs. Extracts were prepared and the immunoprecipitates with anti-CyclinB1 antibody (lanes 1 and 2) and input extracts (lanes 3 and 4;
20% of the extract used for immunoprecipitation) were analyzed by western blotting. (B) HeLa cells were treated with control or Cdc7-D siRNA,
followed by transfection of a Flag-tagged 14-3-3s-expressing plasmid. Extracts were prepared at 48 hrs after siRNA transfection and the
immunoprecipitates with anti-Flag antibody (lanes 1 and 2) or normal (control) IgG (lanes 3 and 4) and input extracts (lanes 5 and 6; 17% of the
extract used for immunoprecipitation) were analyzed by western blotting. The binding of Cdc2/CyclinB1 with 14-3-3s increases after Cdc7 siRNA
treatment, suggesting that 14-3-3s retains CyclinB1 in the cytoplasm after Cdc7 depletion in HeLa cells. (C and D) HeLa cells were treated with Cdc7-
D siRNA, 14-3-3s and Cdc7-D siRNAs, 14-3-3s siRNA and control siRNA for 48 hrs. (C) Western blot analysis of the whole cell extracts. (D) DNA
contents of the cells in C were analyzed by FACS (10,000 cells for each) and the fraction of the cells in each cell cycle stage is presented. (E) HeLa cells
expressing mKO2-CyclinB1 were treated with Cdc7-D and/or 14-3-3s siRNA as indicated. The time (hr) between the first appearance of cytosolic
mKO2-CyclinB1 signals and its translocation into the nucleus was measured using the time lapse images, which started at 24 hrs after siRNA
transfection. The P-value of the two-tailed unpaired t-test was calculated by Prism software. Co-depletion of 14-3-3s led to a decrease in the overall
CyclinB1 protein level (C), reduced cell death (D), and reduced the duration of its cytoplasmic retention (E).
doi:10.1371/journal.pone.0036372.g003
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depletion in HeLa cells, but not in U2OS or NHDF cells
(Fig. 5A). This activation of MK2 in Cdc7-depleted HeLa cells
could be due to direct activation of MK2 by Cdc7-induced
replication stress. Alternatively, increase of G2 phase cells by Cdc7
depletion may contribute to activation of MK2, since MK2 is
known to be more active in G2 and M phases. Co-depletion of
Cdc7 and MK2 reduced the Cyclin B1 and AuroraA protein levels
and Cdc25C Ser216 phosphorylation, suggesting that mitosis is
partially restored (Fig. 5B). It also reduced the binding of 14-3-3s
and CyclinB1/Cdc2 (Fig. 5C). However, co-depletion of Cdc7
and MK2 did not prevent HeLa cell death, presumably because
MK2 depletion alone induced significant cell death (data not
shown).
The time required for nuclear translocation after co-depletion of
Cdc7 and MK2 was shortened close to the control level.
Furthermore, the G2 elongation observed after Cdc7 depletion
was canceled also by co-depletion of ATR or p38 with Cdc7
(Fig. 5D). These results indicate that this G2 checkpoint depends
on ATR-regulated MK2 activation.
Cytoplasmic accumulation of CyclinB1 does not occur in
p53-positive U2OS or HCT116 after Cdc7 depletion
Although Cdc7 depletion in U2OS cells (human osteosarcoma),
induced vigorous cell death, the levels of the mitotic kinases did
Figure 4. Expression of nuclear localization signal-targeted CyclinB1 partially reduces cell death in Cdc7-depleted HeLa cells. (A)
HeLa cells expressing mKO2-NLS-CyclinB1 (left) or mKO2-CyclinB1 (right) were treated with control or Cdc7-D siRNA and were monitored by Olympus
LCV100. Dead cells were counted in the time lapse images at the times indicated. Cell death was suppressed in mKO2-NLS-CyclinB1 expressing HeLa
cells up to 72 hrs (at which half of the Cdc7-depleted HeLa cells are usually dead). mKO2-NLS-CyclinB1 plasmid was constructed by inserting the NLS
sequence (PPKKKRKVEDP) from the SV40 large T antigen into the mKO2-CyclinB1 plasmid between mKO2 and CyclinB1. About 200 or 60 cells
expressing mKO2-NLS-CyclinB1 or mKO2-CyclinB1, respectively, were counted. ‘‘n’’ represents the numbers of independent experiments conducted.
(B) HeLa cells expressing mKO2-CyclinB1 (WT) or mKO2-NLS-CyclinB1 (NLS) were treated with control or Cdc7-D siRNA and the duration of CyclinB1
expression before entry into M phase was measured in the time lapse images. Upon Cdc7 depletion, NLS cells did not accumulate the tagged
CyclinB1 in cytoplasm, and continued through the cell cycle more or less normally. (C) HeLa cells were treated with indicated siRNAs for 48 hrs. DNA
contents were analyzed by FACS (10,000 cells for each) and the fractions of sub-G1 population were calculated and presented. Co-depletion of
CyclinB1 reduced the cell death induced by Cdc7-D siRNA in HeLa cells. (D) HeLa cells expressing mKO2-CyclinB1 (WT) were treated with Cdc7-D or
Cdc7-D+CyclinB1 siRNA and the time (hr) between the first appearance of cytosolic mKO2-CyclinB1 signal and its translocation into the nucleus was
measured in the time lapse images of each cell population. Down-regulation of CyclinB1 expression shortened the G2 arrest induced by Cdc7
depletion. In (B) and (D), the P-values of the two-tailed unpaired t-test were calculated by Prism software.
doi:10.1371/journal.pone.0036372.g004
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expressing mKO2-CyclinB1, and examined the effect of Cdc7
siRNA on the CyclinB1 dynamics. In this cell line, we did not
observe any accumulation of CyclinB1 in the cytoplasm after Cdc7
depletion. The time required for nuclear translocation in Cdc7-
depleted U2OS cells was similar to that of control cells (Fig. 6A).
However, it became longer when p53 was co-depleted (Fig. 6A).
The CyclinB1 protein level slightly increased after co-depletion of
Cdc7 and p53 in U2OS (Fig. 6B). We next examined a colon
cancer cell line, HCT116. In p53-positive HCT116 cancer cells,
the levels of mitotic proteins such as CyclinB1 and Plk1 decreased
after Cdc7 depletion presumably due to G1 arrest (Fig. 7A).
Concomitantly, Cdc2/CyclinB1 activity was also reduced in
Cdc7-depleted p53-positive HCT116 cells (Fig. 7B). The time
required for nuclear translocation in Cdc7-depleted p53-positive
HCT116 cells was similar to that of control cells (Fig. 7C, left
panel). In contrast, Cdc2/CyclinB1 activity in p53-negative
HCT116 after Cdc7 depletion was almost the same as that of the
control (Fig. 7B). Furthermore, as seen in HeLa cells, the time
required for nuclear translocation in Cdc7-depleted p53-negative
HCT116 cells was longer than that of the control (Fig. 7C, right
panel). This G2 elongation was canceled by co-depletion of Cdc7
and MK2 in p53-negative HCT116 cells (Fig. 7C, right panel).
These results indicate that G2 phase elongation after Cdc7
depletion depends on the absence of p53 protein [15,30–32].
Recently, it was reported that the FoxO3 transcription factor is
involved in G1 arrest, caused by depletion of Cdc7 in normal cells
[16]. FoxM1, another Fox family member, is known to regulate
expression of mitotic regulators such as Plk, CyclinB1 and CyclinA
after DNA damage [33–36]. Expression of FoxM1 is negatively
regulated by p53 [37,38]. In HeLa, we show that the mRNA levels
of FoxM1 increased after Cdc7 depletion (Fig. 8A), which may
also be partly responsible for an increase of FoxM1 protein levels
under the same condition. These findings suggest that these Fox
family transcription factors may be involved in cell cycle arrest and
induction of cell death by Cdc7 depletion in p53-negative cells.
Double knockdown of Cdc7 and FoxM1 in HeLa cells dramat-
ically reduced the CyclinB1 mRNA level compared to Cdc7
depletion alone. The CyclinB1 protein level also decreased by co-
depletion of Cdc7 and FoxM1, but not to the extent of the mRNA
level (Fig. 8B). FoxM1 depletion, however, did not abrogate the
G2 arrest or reduce cell death (Fig. 8D, data not shown). In
p53-positive HCT116 cells, the mRNA levels of FoxM1 did not
change significantly, probably due to negative regulation of
FoxM1 expression by p53 [37]. CyclinB1 and Plk mRNA levels
also did not change after Cdc7 depletion in this cell line (data not
shown). Thus, increased expression of FoxM1 may be at least
partially responsible for the increased CyclinB1 protein level in
Cdc7-depleted HeLa cells, which are deficient in p53, although it
may not be essential for cytoplasmic accumulation of CyclinB1
Figure 5. MK2 is activated in Cdc7-depleted HeLa cells and is required for cytoplasmic accumulation of CyclinB1. (A) HeLa (lanes 1, 2,
7 and 8), U2OS (lanes 3 and 4) and NHDF (lanes 5 and 6) cells were treated with control or Cdc7 siRNA and the whole cell extracts were run on a
phosgel and analyzed by western blotting. Lanes 7 and 8, extracts from Cdc7 siRNA-treated HeLa cells were non-treated (2) or treated with l-
phosphatase (+). Arrowheads indicate the phosphorylated MK2 band. (B) HeLa cells were treated with control siRNA (lanes 1 and 5), Cdc7 siRNA
(lanes 2 and 6), Cdc7 and MK2 siRNAs (lanes 3 and 7) and MK2 siRNA (lanes 4 and 8) for 48 hrs, and CSK-soluble (lanes 1–4; Sup) and -insoluble (lanes
5–8; Ppt) proteins were analyzed by western blotting. Tubulin and LaminB are shown as loading controls. (C) Glutathion Sepharose 4B beads carrying
GST-14-3-3s protein was incubated for 1 hr at 4uC with CSK-soluble extracts of HeLa cells treated with siRNA, as shown. Bound proteins were
examined by Western blotting. ‘‘Input’’ represents only the extracts without added GST-14-3-3s protein. Cdc7 and MK2 co-depletion reduced the
binding between 14-3-3s and Cdc2/CyclinB1. (D) HeLa cells expressing mKO2-CyclinB1 were treated with indicated siRNAs. The time (hr) between
the first appearance of cytosolic mKO2-CyclinB1 signal and its translocation into the nucleus was measured in the time lapse images. Co-depletion of
MK2, p38 (upstream kinase of MK2) or ATR reduced cytoplasmic retention of CyclinB1 (G2 elongation) was observed in Cdc7-depleted HeLa cells. The
P-values of the two-tailed unpaired t-test were calculated by Prism software. Cdc7-D siRNA was used in all the experiments.
doi:10.1371/journal.pone.0036372.g005
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PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e36372Figure 6. CyclinB1 does not accumulate in cytoplasm in Cdc7-depleted U2OS cells. (A) U2OS cells expressing mKO2-CycinB1 were
treated with siRNAs and time lapse images were recorded by LCV100. The time (hr) between the first appearance of cytosolic mKO2-CyclinB1
signal and its translocation into the nucleus was measured in the time lapse images of each cell population. In Cdc7-depleted U2OS, CyclinB1
does not accumulate in cytoplasm. However, co-depletion of Cdc7 and p53 caused CyclinB1 accumulation in cytoplasm for a longer period.
The P-values of the two-tailed unpaired t-test were calculated by Prism software. (B) Western analysis of the whole cell extracts of U2OS cells
treated with indicated siRNAs for 48 hrs. A phosgel was used for the detection of MK2. Other proteins were detected on a 4–12% gradient
gel.
doi:10.1371/journal.pone.0036372.g006
Figure 7. The CyclinB1 protein level and Cdc2-CyclinB1 kinase activity decrease in p53-positive HCT116 cells after Cdc7
depletion. (A) p53-positive or -negative HCT116 cells were treated with control or Cdc7-D siRNA for 48 hrs, and whole cell extracts were analyzed
by western blotting. (B) CSK-soluble extracts were prepared from the same cells as in (A) and immunoprecipitation was conducted with anti-
CylinB1 antibody. Cdc2-CyclinB1 kinase activity was measured with Histone H1 as a substrate (upper panel), as described in ‘‘Materials and
Methods’’. The graph below shows quantification of the level of phosphorylation. Lower panel, western blotting analyses of CyclinB1 proteins in
the immunoprecipitates used for kinase assays. (C) p53-positive (left) or -negative (right) HCT116 cells expressing mKO2-CyclinB1 were treated with
indicated siRNA and time lapse images were recorded. The time (hr) between the first appearance of cytosolic mKO2-CyclinB1 signal and its
translocation into the nucleus was measured in the time lapse images. The P-values of the two-tailed unpaired t-test was calculated by Prism
software.
doi:10.1371/journal.pone.0036372.g007
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that cytoplasmic sequestration and accumulation of CyclinB1 is a
predominant factor for cell death in p53-negative cells.
Efficient induction of cell death in cancer cells by
combination of Cdc7 siRNA and conventional anti-cancer
agents
Combinational therapy is sometimes efficient in treating cancer
patients. The results described above and from other reports
indicate that Cdc7 could be a novel effective target for cancer
therapy, the inhibition of which might induce cancer cell-specific
cell death through novel and distinct pathways in both p53-
positive and -negative cancer cells [15,30–32]. We used p53-
positive and -negative HCT116, a colon cancer cell line, and
compared the effects of Cdc7 depletion. As reported previously,
both cells underwent cell death after Cdc7-depletion. We then
examined the effect of conventional cancer treatment genotoxic
agents, etoposide (topoisomerase II inhibitor) or 5FU (59
fluorouracil; irreversible inhibitor of thymidylate synthase), which
would inhibit the DNA chain elongation process, for cell death-
inducing effect of Cdc7 siRNA or a Cdc7 inhibitor in p53-positive
and -negative HCT116 cells.
We noted that the co-treatment with etoposide synergistically
increased the sub-G1 population in Cdc7 siRNA-treated p53-
positive HCT116 compared to the cells treated with the drug
alone. This stimulation of cell death by co-treatment of the Cdc7
depletion and the genotoxic agents was not observed in p53-
negative HCT116. (Fig. 9A). Furthermore, we noted that the co-
treatment with etoposide or 5FU with a Cdc7 chemical inhibitor
also significantly increased the sub-G1 population in p53-positive,
but not in p53-negative HCT116 cells (Fig. 9B). We next
conducted colony formation assays after treating the cells with a
combination of etoposide and the Cdc7 chemical inhibitor. The
synergistic effect of etoposide and the Cdc7 inhibitor on colony
formation was once again observed in p53-positive HCT116 cells
only (Fig. 9C). These results suggest a potential novel cancer
therapy involving the combination of Cdc7 inhibition and
conventional anti-cancer agents that is effective specifically in
p53-positive cancer cells.
Discussion
Cancer cell death induced by Cdc7 depletion
The blocking of DNA replication in eukaryotic cells normally
induces checkpoint responses which slow down the ongoing forks
and prevent firing of new replication origins. This would sustain
cell viability by restraining aberrant DNA replication. In cancer
cells, the cells often enter lethal S phase due to partial defect in
checkpoint pathways. Indeed, normal cells would undergo cell
death by arrest of DNA replication forks when one or more of the
checkpoint pathways are shut down [15,16,39].
In many cancer cells, Cdc7 depletion causes vigorous cell death,
which is independent of the p53 status. Use of Fucci, a fluorescent
Figure 8. FoxM1 mRNA level increases after Cdc7 depletion in HeLa and p53-negative HCT116. (A) HeLa cells were treated with
indicated siRNAs for 24 hrs. FoxM1 (left), Plk1 (middle) and CyclinB1 (right) mRNA levels are presented. (B) Western analysis of the whole cell extracts
of HeLa cells treated with indicated siRNAs for 48 hrs. A phosgel was used for the detection of MK2. Other proteins were separated on a 4–12%
gradient gel. (C) The FoxM1 mRNA levels of HCT116 (p53-positive and -negative) cells treated with control or Cdc7 siRNA for 24 hrs. In A and C, mRNA
levels were quantified by real time-PCR and the relative values normalized by the level of GAPDH mRNA are presented. (D) HeLa cells treated with
indicated siRNAs for 48 hrs were fixed with 4% paraformaldehyde for 10 min and stained with anti-CyclinB1 antibody. Fractions of the cells showing
nuclear localization of CyclinB1 are shown. Cdc7-D siRNA was used in these experiments.
doi:10.1371/journal.pone.0036372.g008
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permitted us to determine the cell cycle stage at which cells
undergo cell death upon depletion of Cdc7. Cdc7-depleted HeLa-
Fucci cells die at both red (G1) and green (S/G2/M) states. On the
other hand, about 70% of the cell death in Cdc7-depleted U2OS-
Fucci cells appears to occur in ‘‘green’’ cells and predominantly
during S phase. This conclusion is consistent with our observation
that U2OS cells expressing mKO2-CyclinB1 rarely underwent cell
death when mKO2 was expressed (indicative of late S/G2/M).
Thus, timing of cell death induced by Cdc7 depletion may differ in
HeLa and U2OS cells. These results indicate that Cdc7 depletion-
dependent cell death can occur through multiple mechanisms and
that the p53 state may affect the choice of cell death modes.
G2 cell cycle elongation induced by Cdc7 depletion is
dependent on the p53 status
We showed that CyclinB1 accumulates in the cytoplasm of
Cdc7-depleted HeLa cells, but not in p53-positive U2OS or
HCT116 cells. The accumulation of CyclinB1 is due to 14-3-3s,
and co-depletion of 14-3-3s leads to abrogation of CyclinB1
accumulation as well as partial rescue of viability. ATR-MK2,
activated by Cdc7 depletion, is required for CyclinB1 accumula-
tion. Abrogation of CyclinB1 accumulation by other methods also
resulted in less cell death, indicating that the cytoplasmic
sequestration/accumulation of CyclinB1 and the following abrupt
transport into nuclei may be a predominant factor for cell death in
p53-negative cells.
It was reported in hematopoietic cells that ectopic overexpres-
sion of CyclinB1 causes apoptosis. Furthermore, the elevated level
of CyclinB1 stimulates c-irradiation induced cell death [40]. It was
also reported that nuclear accumulation of CyclinB1 causes
apoptosis in cancer cells [29]. We see more than half of the cell
population die after translocation of the accumulated CyclinB1
into nuclei, which causes transient but marked increases of nuclear
CyclinB1, leading to aberrant chromosome separation and cell
division. We also observed cell death in those cells accumulating
CyclinB1 in cytoplasm (Fig. 2C).
In p53-positive cells, in contrast, Cdc7 depletion led predom-
inantly to death during S phase. This may be due to p53-mediated
G1 or S phase arrest, that eventually leads to aberrant entry into S
phase. FoxM1 is required for transcriptional up-regulation of
mitotic regulators in Cdc7-depleted HeLa cells (Fig. 8). p53-
mediated inhibition of FoxM1 may also contribute to reduced
mitotic regulators in Cdc7-depleted p53-positive cancer cells.
Addition of conventional anti-cancer drugs facilitates
Cdc7 depletion-induced cancer cell death
Combinations of multiple anti-cancer drugs can sometimes be
more effective and have less side effects when treating cancer
patients than the use of single anti-cancer drugs. However, the
rationale behind effective multi-drug cancer therapy strategies has
Figure 9. Coadministration of conventional anti-cancer drugs enhances cell death in a p53-dependent manner. (A) p53-positive
(upper) or -negative (lower) HCT116 cells were treated with Cdc7-D or control siRNA for 24 hrs, followed by treatment with DMSO or 10 mM
etoposide (Wako) for 32–40 hrs. (B) p53-positive (upper) or -negative (lower) HCT116 cells were treated with indicated chemicals (10 mM etoposide or
5FU (Wako) and 1 mM Cdc7 inhibitor (Calbiochem)) for 16 hrs. In A and B, DNA contents were analyzed by FACS (10,000 cells for each) and the
fractions of sub-G1 population were calculated and presented. Synergistic effect of etoposide and 5FU on cell death induced by Cdc7 inhibition was
observed in a p53-positive HCT116 but not in p53-negative HCT116. (C) Colony formation assays were conducted in p53-positive HCT116 cells. Cells
treated with drugs for 16 hrs were collected and 500 cells were seeded in a 3.5 cm plate and cultured. The numbers of colonies were counted after 7
days. ‘‘n’’ represents the numbers of independent experiments conducted.
doi:10.1371/journal.pone.0036372.g009
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5FU, frequently-used anti-cancer agents, on Cdc7 inhibition-
induced cell death in p53-positive or p53-negative HCT116 cells.
The Cdc7 inhibitor used in this experiment showed delayed S and
G2/M phase progression and accumulated CyclinB1 in HeLa cells
(Fig. S4). We noted that both etoposide and 5FU augmented the
cell death effect of Cdc7 inhibition in p53-positive HCT116 but
not in p53-negative cells (Fig. 9). It is speculated that cell death
during S phase in Cdc7-inhibited p53-positive HCT116 is further
stimulated by the inhibition of DNA chain elongation through
etoposide or 5FU. Meanwhile, in p53-negative HCT116 cells, cell
death, induced mostly by aberrant M phase progression from G2-
arrest, is not affected significantly by the added S phase
inhibitions. Similar effect of etoposide on cancer cell death
induced by Cdc7 depletion was previously reported [41]. These
results suggest potentially effective cancer therapy strategies
depending on the genotype of tumors. In p53-positive cancer
cells, a combination of inhibitors of DNA replication initiation and
genotoxic agents interfering the DNA chain elongation process
may be an effective measure for cell death induction, whereas
combination of Cdc7 inhibition with genotoxic agents targeting
G2-M phase progression could be an effective measure in p53-
negative cancer cells. The latter possibility is now being tested.
In summary, we show that different cell death pathways are
induced in cancer cells by inhibition of Cdc7 kinase, depending on
the p53 status (Fig. 10). Cdc7 depletion would induce ‘‘defective
initiation’’ which may send checkpoint signals directly to ATM/
ATR or through DNA damages caused by aberrant initiation of
DNA replication in the absence of Cdc7. In the absence of p53,
aberrant S phase may proceed to completion but the activated
checkpoint could induce G2 elongation through MK2, eventually
leading to post-mitotic cell death. In the presence of p53, the
initiation defect caused by Cdc7 inhibition may predominantly
cause transient G1 or S phase arrest. Aberrant progression into S
phase and generation of pathological stalled fork structures under
these conditions may lead to collapsed replication forks and
generate lethal DNA damages, leading to cell death in S phase. A
p53-induced pro-apoptotic factor may also contribute to cell
death. In normal cells with wild-type p53 and all other checkpoint
machinery functioning, a defect in initiation would be effectively
detected and stalled before entering abortive S phase, thus
permitting the cells to escape from cell death [16,42].
Materials and Methods
Cell lines and the cells expressing fluorescence-tagged
proteins
All cells including HeLa, U2OS, HCT116 (p53-positive),
NHDF and 293T cells were obtained from ATCC, and were
maintained as described previously [5,15,19]. Lentiviruses for
Figure 10. Proposed pathways of cell death induced in cancer cells by inhibition of Cdc7 kinase. Inhibition of initiation of DNA
replication by suppression of Cdc7 kinase leads to activation of ATM/ATR, which may result in the activation of three checkpoint kinases, Chk1, MK2,
and Chk2. Since Cdc7 is actively required for activation of Chk1 [19,46], Chk1 is not activated under this condition. Activated MK2 may phosphorylate
Cdc2/Cyclin B1, which in turn may be recognized and bound by 14-3-3s protein and is sequestered in cytoplasm. Cdc7 depletion can induce DNA
damages in cancer cells [19] and activated Chk2 would stabilize the FoxM1 transcription factor, which would induce the expression of CyclinB1 [47].
The accumulated CyclinB1 protein is abruptly transported into nuclei and mitotic catastrophe or post-mitotic cell death is induced. In p53-positive
cancer cells, p53, activated through ATM/ATR, would induce G1 delay as well as S phase delay possibly through induction of p21. p53 inhibits
transcription of FoxM1 [37,38], thus preventing the induction of Cyclin B1. However, aberrant S phase progression in the absence of Cdc7 would
induce cell death in p53-positive cancer cells.
doi:10.1371/journal.pone.0036372.g010
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scribed previously [18]. mKO2-CyclinB1 and mKO2-AuroraA
expressing plasmids were constructed by replacing the Cdt1 part
of the mKO2-Cdt1 vector with the full-length CyclinB1 and
AuroraA, respectively. p53-negative HCT116 cells were obtained
from Dr. B. Vogelstein.
Preparation of extracts, western blotting and
immunoprecipitation
Cell extract preparation, western blotting and immunoprecip-
itation were conducted as described previously [5,19].
siRNA, antibodies and inhibitors
siRNAs and antibodies used are described in supplementary
information (Table S1). The Cdk9/Cdc7 inhibitor was from
Calbiochem.
Transfection
Plasmid DNA transfection into 293T cells was conducted by
using Lipofectamine2000 reagent or PEI solution [43,44] to
prepare lentiviral solutions. Plasmid DNA transfection into HeLa
was conducted by using FuGENE HD (Roche). Oligofectamine
transfection reagent (Invitrogen) was used for transfection of
siRNA into HeLa, U2OS and NHDF cells, and X-tremeGENE
siRNA transfection Reagent (Roche) was used for siRNA
transfection into HCT116 cells.
Time lapse analyses of fluorescent cells
For live cell imaging, cells were plated in a glass-bottomed dish,
m-Dish (Ibidi), transfected with siRNAs and observed under
LCV100 microscopy (Olympus) equipped with an objective lens
(Olympus, UAPO 403/340 N.A.=0.90). For fluorescence imag-
ing, the halogen lamp was used with two filter cubes, one for
observing mKO2 fluorescence (with excitation [BP520-540HQ]
and emission [BP555-600HQ] filters), and the other for observing
mAG fluorescence (with excitation [470DF35] and emission
[510WB40] filters). For DIC imaging, the red LED was used
with a filter cube containing an analyzer. Image acquisition and
analyses were performed by using MetaMorph software version
7.1.3 and 7.5.1 (Universal Imaging, Media, PA), respectively.
Prism software (GraphPad Software Co. Ltd.) was used for
analyses of indicated signals from acquired movies and for two-
tailed unpaired t-test.
Immunostaining
For immunostaining, cells were fixed with 4% paraformalde-
hyde for 10 min at room temperature, washed with PBS,
permealysed with 0.1% Triton X-100, and stained by anti-
CyclinB1 antibody overnight at 4uC. After washing, the cells were
stained with FITC-conjugated anti-mouse IgG for 30 min at room
temperature, followed by Hoechst staining. Antibodies were
diluted with dilution buffer (2 mg/ml BSA, 0.2% Tween20 and
10% glycerol). Stained cells were observed under All-in-One
microscopy (Keyence) or FSX100 microscopy (Olympus).
In vitro kinase assays of Cdc2-CyclinB1
Cdc2/CyclinB1 kinase activity was measured by incubating the
anti-CyclinB1 antibody immunoprecipitate with Histone H1 as a
substrate, as described previously [45].
Analyses of proteins on phosgel
10% SDS-PAGE gel containing 25 mM phos-tag AAL-107
(NARD Institute Ltd.) and 50 mM MnCl2 was used to separate
phosphorylated proteins according to the manufacture’s instruc-
tion.
Supporting Information
Figure S1 Cdc7 depletion in cancer and normal cells. (A)
FACS analyses of HeLa or U2OS cells (10,000 cells for each)
treated with control (green) or Cdc7-D (red) siRNA for times
indicated. Sub-G1 population increased after Cdc7 depletion in
both cell lines. (B) FACS analyses of NHDF cells (10,000 cells for
each) treated with Cdc7-D or control siRNA for 48 hrs. BrdU was
incorporated into cells for 30 min and the harvested cells were
stained with anti-BrdU antibody and PI as described in ’’Materials
and Methods’’. (C) Western blot analyses of the whole cell extracts
of NHDF cells treated with control or Cdc7-D siRNA for 48 hrs.
In Cdc7-depleted NHDF cells, CyclinB1 protein level decreased
with concomitant decrease of mitotic cells (indicated by the
decreased phosphorylated serine 10 signal of Histone H3). (D)
NHDF cells expressing Fucci were treated with Cdc7-D (lower) or
control siRNA (upper) and time lapse images were recorded.
Images taken from the time lapse data at the times indicated are
presented. Red cells accumulate in Cdc7 siRNA-treated NHDF
cells, indicating the arrest in G1 phase.
(EPS)
Figure S2 Accumulation of CyclinB1 in the cytoplasm
and cell death are observed with other siRNA in HeLa
cells. (A) The time (hr) between the first appearance of cytosolic
mKO2-CyclinB1 signal and its translocation into nucleus was
measured in the time lapse images of HeLa/mKO2-CyclinB1 cells
treated with control or various Cdc7 siRNAs (Cdc7-D, Cdc7-A
and Cdc7-new1). Cytoplasmic accumulation of Cdc7 is observed
with Cdc7-A and Cdc7-new1 siRNAs as well. (B) FACS analyses
of HeLa cells (10,000 cells for each) treated with control (green) or
Cdc7-A (red) siRNA for times indicated. Sub-G1 population
increased after Cdc7 depletion.
(EPS)
Figure S3 Cdc7 depletion in HeLa cells expressing
mKO2-AuroraA. (A) HeLa cells stably expressing mKO2-
AuroraA were established and treated with control (left) or
Cdc7-D (right) siRNA. Time lapse images were recorded by
Olympus LCV100. Images taken from the time lapse data at the
times indicated are shown. Red signals show mKO2-AuroraA.
Cdc7 depletion leads to increased duration of red signals and
subsequent cell death, suggesting that cells are arrested in G2
phase before undergoing cell death. Bar: 20 mm. (B) HeLa cells
expressing mKO2-AuroraA were cultured on glass-bottomed
dishes and were labeled with EdU for 10 min. Cells stained with
Crick IT EdU detection kit (Invitrogen) were observed by FSX100
microscopy (Olympus). Green, EdU (DNA synthesis); red, mKO2-
AuroraA. mKO2-positive cells and EdU positive cells do not
overlap. Bar: 153 mm. (C) The time (hr) between the first
appearance of nuclear mKO2-AuroraA signals and the cells’
transition into prophase (round cells) was measured from the time
lapse data and is presented for control or Cdc7 siRNA (Cdc7-D, -
A and -new1)-treated HeLa cells (movies S5 and S6). The P-
values of the two-tailed unpaired t-test were calculated by Prism
software.
(EPS)
Figure S4 Cdc7 inhibitor delayed cell cycle progression
with accumulated CyclinB1 protein in HeLa. (A) HeLa
cells were grown in the presence of 2.5 mM thymidine for 15–
16 hrs, followed by successive growth without thymidine for 9 hrs
and with thymidine for 15–16 hrs. The G1/S-arrested cells were
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PLoS ONE | www.plosone.org 12 May 2012 | Volume 7 | Issue 5 | e36372released into cell cycle for indicated times in the presence of 1 mM
Cdc7 inhibitor or DMSO and FACS and Western analyses were
conducted. The Cdc7 inhibitor delayed S, G2/M phase
progression and accumulated CyclinB1. (B) HeLa (left) and
U2OS (right) cells were treated with 1 mM Cdc7 inhibitor for
24 hrs and harvested. FACS and Western analyses were
conducted. CyclinB1 accumulation was observed only in HeLa
cells.
(EPS)
Table S1 siRNAs and antibodies used in this study.
(EPS)
Movie S1 HeLa cells expressing Fucci (mKO2-hCdt1
(red) for G1 and mAG-hGeminin (green) for S/G2/M)
were treated with control siRNA and time lapse image
was recorded by LCV100 Microscopy (Olympus). Both
videos start at 24 hrs after siRNA transfection. Total imaging time
was 72 hr. Images were acquired every 60 min. Playback speed is
216006real time.
(AVI)
Movie S2 HeLa cells expressing Fucci (mKO2-hCdt1
(red) for G1 and mAG-hGeminin (green) for S/G2/M)
were treated with Cdc7-D siRNA and time lapse image
was recorded by LCV100 Microscopy (Olympus). Both
videos start at 24 hrs after siRNA transfection. Total imaging time
was 72 hr. Images were acquired every 60 min. Playback speed is
216006real time.
(AVI)
Movie S3 HeLa cells expressing mKO2-CyclinB1 (red)
were treated with control and time lapse image was
recorded by LCV100 Microscopy (Olympus). Both videos
start at 24 hrs after siRNA transfection. Total imaging time was
42 hr. Images were acquired every 40 min. Playback speed is
137456real time.
(AVI)
Movie S4 HeLa cells expressing mKO2-CyclinB1 (red)
were treated with Cdc7-D siRNA and time lapse image
was recorded by LCV100 Microscopy (Olympus). Both
videos start at 24 hrs after siRNA transfection. Total imaging time
was 42 hr. Images were acquired every 40 min. Playback speed is
137456real time.
(AVI)
Movie S5 HeLa cells expressing mKO2-AuroraA (red)
were treated with control siRNA and time lapse image
was recorded by LCV100 Microscopy (Olympus). Both
videos start at 24 hrs after siRNA transfection. Total imaging time
was 60 hr. Images were acquired every 40 min. Playback speed is
144006real time.
(AVI)
Movie S6 HeLa cells expressing mKO2-AuroraA (red)
were treated with Cdc7-D siRNA and time lapse image
was recorded by LCV100 Microscopy (Olympus). Both
videos start at 24 hrs after siRNA transfection. Total imaging time
was 60 hr. Images were acquired every 40 min. Playback speed is
144006real time.
(AVI)
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